DK3506904T3 - Behandling af demens - Google Patents
Behandling af demens Download PDFInfo
- Publication number
- DK3506904T3 DK3506904T3 DK17761842.8T DK17761842T DK3506904T3 DK 3506904 T3 DK3506904 T3 DK 3506904T3 DK 17761842 T DK17761842 T DK 17761842T DK 3506904 T3 DK3506904 T3 DK 3506904T3
- Authority
- DK
- Denmark
- Prior art keywords
- dementia
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1614834.8A GB201614834D0 (en) | 2016-09-01 | 2016-09-01 | Treatment of dementia |
PCT/EP2017/071437 WO2018041739A1 (en) | 2016-09-01 | 2017-08-25 | Treatment of dementia |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3506904T3 true DK3506904T3 (da) | 2021-01-04 |
Family
ID=57139937
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17761842.8T DK3506904T3 (da) | 2016-09-01 | 2017-08-25 | Behandling af demens |
Country Status (18)
Country | Link |
---|---|
US (1) | US10842796B2 (da) |
EP (1) | EP3506904B1 (da) |
JP (1) | JP7066679B2 (da) |
KR (1) | KR102559354B1 (da) |
CN (1) | CN109890391B (da) |
AU (1) | AU2017318333B2 (da) |
CA (1) | CA3034625A1 (da) |
DK (1) | DK3506904T3 (da) |
ES (1) | ES2847929T3 (da) |
GB (1) | GB201614834D0 (da) |
HR (1) | HRP20210162T1 (da) |
MX (1) | MX2019002429A (da) |
MY (1) | MY187564A (da) |
PL (1) | PL3506904T3 (da) |
PT (1) | PT3506904T (da) |
SG (1) | SG11201901125TA (da) |
SI (1) | SI3506904T1 (da) |
WO (1) | WO2018041739A1 (da) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102718730B (zh) | 2006-07-11 | 2018-06-05 | 维斯塔实验室有限公司 | 二氨基吩噻嗪*化合物的合成和/或纯化方法 |
CA3106152A1 (en) * | 2018-07-26 | 2020-01-30 | Wista Laboratories Ltd. | Optimised dosage of diaminophenothiazines in populations |
JP7401531B2 (ja) | 2018-09-05 | 2023-12-19 | ゲンティング タークス ダイアグノースティク センター エスディエヌ ビーエイチディ | 神経変性疾患のためのネットワーク法 |
GB201909454D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Enhancers |
GB201909493D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Therapeutic interactions |
GB201909506D0 (en) | 2019-07-02 | 2019-08-14 | Wista Lab Ltd | Synaptopathies |
WO2023232764A1 (en) | 2022-05-31 | 2023-12-07 | Wista Laboratories Ltd. | Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds |
US20240115579A1 (en) * | 2022-09-22 | 2024-04-11 | Galenicum Health S.L.U. | Pharmaceutical compositions and manufacturing methods thereof |
EP4342451A1 (en) * | 2022-09-22 | 2024-03-27 | Galenicum Health SLU | Pharmaceutical compositions and manufacturing methods thereof |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
DE60324788D1 (de) * | 2002-05-31 | 2009-01-02 | Lundbeck & Co As H | Kombination aus einem nmda-antagonist und acetylcholinesterase-hemmern zur behandlung der alzheimer-krankheit |
AU2005286235C1 (en) | 2004-09-23 | 2013-08-22 | Wista Laboratories Ltd. | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including Methylthioninium Chloride (MTC) |
CA2645919C (en) | 2006-03-29 | 2016-05-31 | Wista Laboratories Ltd. | Thioninium compounds and their use |
ATE478058T3 (de) | 2006-03-29 | 2010-09-15 | Wista Lab Ltd | 3,7-diamino-10h-phenothiazinsalze und ihre verwendung |
FR2899107B1 (fr) * | 2006-03-30 | 2008-06-13 | Neurokin Entpr Unipersonnelle | Utilisation de la (s)-roscovitine pour la fabrication d'un medicament |
CN102718730B (zh) | 2006-07-11 | 2018-06-05 | 维斯塔实验室有限公司 | 二氨基吩噻嗪*化合物的合成和/或纯化方法 |
FR2903696B1 (fr) | 2006-07-12 | 2011-02-11 | Provence Technologies | Procede de purification de composes diaminophenothiazium |
US9034890B2 (en) * | 2006-11-15 | 2015-05-19 | Steven A. Rich | Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases |
PL2167095T3 (pl) | 2007-06-19 | 2019-11-29 | Wista Lab Ltd | Związki fenotiazynowe do leczenia łagodnych zaburzeń poznawczych |
MY161656A (en) | 2007-10-03 | 2017-04-28 | Wista Lab Ltd | Therapeutic use of diaminophenothiazines |
EP2963024B1 (en) | 2009-09-24 | 2018-07-18 | WisTa Laboratories Ltd. | Crystalline methylthioninium chloride hydrates - part 2 |
JP5918136B2 (ja) | 2009-09-24 | 2016-05-18 | ウィスタ ラボラトリーズ リミテッド | プロセス |
CN105853439A (zh) * | 2011-02-11 | 2016-08-17 | 维斯塔实验室有限公司 | 吩噻嗪二胺鎓盐和其用途 |
CN102936244B (zh) * | 2012-12-04 | 2015-02-04 | 合肥工业大学 | 一种他克林-吩噻嗪异二联体类化合物及其制备方法 |
-
2016
- 2016-09-01 GB GBGB1614834.8A patent/GB201614834D0/en not_active Ceased
-
2017
- 2017-08-25 MY MYPI2019001119A patent/MY187564A/en unknown
- 2017-08-25 JP JP2019511720A patent/JP7066679B2/ja active Active
- 2017-08-25 US US16/329,611 patent/US10842796B2/en active Active
- 2017-08-25 ES ES17761842T patent/ES2847929T3/es active Active
- 2017-08-25 PT PT177618428T patent/PT3506904T/pt unknown
- 2017-08-25 SI SI201730630T patent/SI3506904T1/sl unknown
- 2017-08-25 SG SG11201901125TA patent/SG11201901125TA/en unknown
- 2017-08-25 CN CN201780067154.4A patent/CN109890391B/zh active Active
- 2017-08-25 AU AU2017318333A patent/AU2017318333B2/en active Active
- 2017-08-25 KR KR1020197009175A patent/KR102559354B1/ko active IP Right Grant
- 2017-08-25 PL PL17761842T patent/PL3506904T3/pl unknown
- 2017-08-25 CA CA3034625A patent/CA3034625A1/en active Pending
- 2017-08-25 EP EP17761842.8A patent/EP3506904B1/en active Active
- 2017-08-25 MX MX2019002429A patent/MX2019002429A/es unknown
- 2017-08-25 DK DK17761842.8T patent/DK3506904T3/da active
- 2017-08-25 WO PCT/EP2017/071437 patent/WO2018041739A1/en active Application Filing
-
2021
- 2021-02-01 HR HRP20210162TT patent/HRP20210162T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
SI3506904T1 (sl) | 2021-03-31 |
AU2017318333A1 (en) | 2019-04-18 |
MX2019002429A (es) | 2019-07-08 |
ES2847929T3 (es) | 2021-08-04 |
AU2017318333B2 (en) | 2023-05-11 |
JP7066679B2 (ja) | 2022-05-13 |
PL3506904T3 (pl) | 2021-07-26 |
EP3506904A1 (en) | 2019-07-10 |
SG11201901125TA (en) | 2019-03-28 |
WO2018041739A1 (en) | 2018-03-08 |
EP3506904B1 (en) | 2020-12-09 |
MY187564A (en) | 2021-09-30 |
US10842796B2 (en) | 2020-11-24 |
CA3034625A1 (en) | 2018-03-08 |
GB201614834D0 (en) | 2016-10-19 |
PT3506904T (pt) | 2021-02-02 |
CN109890391A (zh) | 2019-06-14 |
US20190192530A1 (en) | 2019-06-27 |
HRP20210162T1 (hr) | 2021-03-19 |
CN109890391B (zh) | 2023-01-31 |
JP2019526571A (ja) | 2019-09-19 |
KR102559354B1 (ko) | 2023-07-26 |
KR20190045273A (ko) | 2019-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3512850T3 (da) | Inhibitorer af menin-mll-interaktionen | |
DK3468966T3 (da) | Inhibitorer af menin-mll-interaktionen | |
DK3134530T3 (da) | Behandling af hyperbilirubinæmi | |
DK3137169T3 (da) | Hæmmere af lysin-specifik demethylase-1 | |
DK3192902T3 (da) | Fremgangsmåde til fremstilling af graphenholdige viscosefibre | |
DK3102576T3 (da) | Dihydropyrrolopyridininhibitorer af ror-gamma | |
DK3506904T3 (da) | Behandling af demens | |
DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
DK3160956T3 (da) | Inhibitorer af lysin-specifik demethylase-1 | |
DK3180331T3 (da) | Polymorfer af selinexor | |
DK3511319T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
DK3461891T3 (da) | Nedstrømsbehandling af en alkalisk phosphatase | |
DK3458052T3 (da) | Kombinationsbehandling af cancer | |
DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
DK3307267T3 (da) | Behandling af multipel sklerose | |
DK3318115T3 (da) | Maskine til behandling af svinegylle | |
DK3261661T3 (da) | Menotropin til behandling af infertilitet | |
DK3368044T3 (da) | Behandling af hepatisk steatose-relateret oligo-ovulation | |
DK3230255T3 (da) | Regulatorer af uhæmmet adfærd | |
DK3430143T3 (da) | Inhibitorer af SRSF1 til behandlingen af neurodegenerative sygdomme | |
DK3201323T3 (da) | Modificering af bakteriofag | |
DK3204352T3 (da) | Hæmmere af lysin-gingipain | |
DK3297619T3 (da) | Terapeutiske anvendelser af L-4-chlorkynurenin | |
DK3522921T3 (da) | Forebyggelse af allergi | |
DK2897382T3 (da) | Forbedring af binaural kilde |